Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J, Wang G, Cheng H, Wei C, Qi K, Sang W, Zhenyu L, Shi M, Li H, Qiao J, Pan B, Zhao J, Wu Q, Zeng L, Niu M, Jing G, Zheng J, Xu K. Cao J, et al. Among authors: wu q. Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29633386 Free article.
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L, Jing G, Sang W, Zhu F, Chen W, Wu Q, Yao Y, Wang G, Zhao J, Zheng J, Li Z, Xu K. Yan Z, et al. Among authors: wu q. Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1. Lancet Haematol. 2019. PMID: 31378662 Clinical Trial.
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, Cheng H, Qiao J, Wang Y, Wang Y, Gao L, Shi M, Sang W, Zhu F, Li D, Sun H, Wu Q, Qi Y, Li H, Wang X, Li Z, Liu H, Zheng J, Qian W, Zhang X, Xu K. Yan Z, et al. Among authors: wu q. Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021. Front Immunol. 2021. PMID: 33708205 Free PMC article.
Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.
Liu Y, Chen W, Yu M, Li H, Cheng H, Cao J, Yan Z, Shi M, Zhu F, Sun H, Sang W, Li D, Wu Q, Chen C, Zheng J, Xu K, Li Z. Liu Y, et al. Among authors: wu q. Transplant Cell Ther. 2022 Feb;28(2):118.e1-118.e5. doi: 10.1016/j.jtct.2021.11.016. Epub 2021 Nov 30. Transplant Cell Ther. 2022. PMID: 34861455 Free article.
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
Shi M, Li L, Wang S, Cheng H, Chen W, Sang W, Qi K, Li Z, Wang G, Li H, Lan J, Huang J, Fei X, Yu M, Li F, Qiao J, Wu Q, Zeng L, Jing G, Zheng J, Gale RP, Xu K, Cao J. Shi M, et al. Among authors: wu q. Am J Hematol. 2022 Jun 1;97(6):711-718. doi: 10.1002/ajh.26506. Epub 2022 Feb 25. Am J Hematol. 2022. PMID: 35179242 Free article.
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
Li H, Zhao L, Sun Z, Yao Y, Li L, Wang J, Hua T, Ji S, Wang S, Cheng H, Shi M, Li Z, Zeng L, Wu Q, Qiao J, Chen C, Zheng J, Cao J, Xu K. Li H, et al. Among authors: wu q. Front Immunol. 2022 Oct 18;13:1019548. doi: 10.3389/fimmu.2022.1019548. eCollection 2022. Front Immunol. 2022. PMID: 36330523 Free PMC article. Clinical Trial.
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, Cao J, Yan Z, Shi M, Cheng H, Zhu F, Sang W, Li D, Chen C, Xu K, Li Z. Liu Y, et al. Among authors: wu q. Front Immunol. 2023 Apr 19;14:1169071. doi: 10.3389/fimmu.2023.1169071. eCollection 2023. Front Immunol. 2023. PMID: 37153543 Free PMC article.
23,590 results
You have reached the last available page of results. Please see the User Guide for more information.